Our Future-Forward Capability and Talent Hacking focuses on leadership roles in general management, commercial, medical / clinical, market access, digital / data analytics and sustainability / circularity.We bring to the table a deep understanding of the complexity of executive roles in a changing world, the value proposition of our client and each role we work on and the impact that candidates can have in the role. Agile, tech- and experience-driven recruitment processes allow us… Show more Our Future-Forward Capability and Talent Hacking focuses on leadership roles in general management, commercial, medical / clinical, market access, digital / data analytics and sustainability / circularity.We bring to the table a deep understanding of the complexity of executive roles in a changing world, the value proposition of our client and each role we work on and the impact that candidates can have in the role. Agile, tech- and experience-driven recruitment processes allow us, together with our clients, to reimagine talent acquisition.Every must-win position that needs to be filled is an opportunity to advance the creation of a future-forward workforce. So that every new leader will make a difference for a company and inspire new ways of thinking, move to the next level.Our innovative executive hacking results in matchmaking with leaders / talent that possess a future-forward mosaic of mindset, experience and skills, often with surprising outcomes.We keep ourselves future-forward and attuned to the mindsets for innovation and entrepreneurship. Show less

Grew global dermatology business through existing portfolio, pipeline and in-licensing, internationalization of portfolio, market creation. This transformed Almirall into the fastest growing dermatology company in Europe.

Built global therapeutic area dermatology, then sold it to Almirall

In an ecosystem with little perceived differentiation and complex partnering, led global commercialisation and partnering of Pantoprazole which became the best-selling product ever to be developed by a German pharmaceutical company (€2.8bn in 2005 vs €650m in 2000), the fastest growing PPI worldwide and the best-selling outside the US, the number 1 in 16 countries